Augmentation of the effect of doxorubicin with low-dose tumor necrosis factor in experimental liver metastasis.
The antitumor activity of recombinant human tumor necrosis factor was studied in vivo as a single agent and in combination with a conventional chemotherapeutic agent. Dosages of tumor necrosis factor of 100 micrograms, 50 micrograms, and 25 micrograms were injected intraportally in Sprague-Dawley rats containing hepatic implants of Walker carcinosarcoma. An effect on the tumor was seen but was associated with a significant acute mortality. Lower dosages of tumor necrosis factor, 10 micrograms, 5 micrograms, and 1 microgram, administered with 10 mg/kg of doxorubicin (Adriamycin) significantly enhanced the antitumor effect of doxorubicin without an acute mortality. This suggests that lower dosages of tumor necrosis factor with conventional chemotherapy may augment the latter's effect without any added toxicity.
Bloom
N D
ND
Department of Surgery, Metropolitan Hospital Center, New York, NY 10029.
Norbergs
D A
DA
Sherman
B
B
Sadjadi
M
M
Ramaswamy
G
G
Jacobs
R
R
Ackerman
N
N
D000818:Animals; D000970:Antineoplastic Agents; D000971:Antineoplastic Combined Chemotherapy Protocols; D002279:Carcinoma 256, Walker / Q000188:drug therapy / Q000556:secondary; D004317:Doxorubicin / Q000494:pharmacology*; D005260:Female; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D004317:Doxorubicin